{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Elevate&page=24",
    "query": {
      "intervention": "Elevate",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 17016,
    "total_pages": 1702,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Elevate&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Elevate&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T13:26:41.806Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01319487",
      "title": "Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "2304 Eye Drops High Dose",
          "type": "DRUG"
        },
        {
          "name": "2304 Eye Drops Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo Eye Drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fovea Pharmaceuticals SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2011-05",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-08-23",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01319487"
    },
    {
      "nct_id": "NCT02113007",
      "title": "Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab plus Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2014-07",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-02-07",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Hollywood, Florida • Orlando, Florida + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113007"
    },
    {
      "nct_id": "NCT04824092",
      "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tafasitamab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Tafasitamab placebo",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 899,
      "start_date": "2021-05-11",
      "completion_date": "2027-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 47,
      "location_summary": "Daphne, Alabama • Anaheim, California • Clovis, California + 44 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Harbor City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04824092"
    },
    {
      "nct_id": "NCT00006071",
      "title": "Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypercholesterolemia",
        "Hypertension"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 120,
      "start_date": "2000-07",
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006071"
    },
    {
      "nct_id": "NCT03974334",
      "title": "Reducing Disparities in the Treatment of Hypertension Using the OWL mHealth Tool",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "OWL-Hypertension 8 Wk Trial",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Paula Gardiner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2019-07-16",
      "completion_date": "2019-12-18",
      "has_results": true,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03974334"
    },
    {
      "nct_id": "NCT03290534",
      "title": "Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Lung Cancer Stage I",
        "Lung Cancer Stage II"
      ],
      "interventions": [
        {
          "name": "CivaSheet",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CivaTech Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2019-03-13",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03290534"
    },
    {
      "nct_id": "NCT03022032",
      "title": "The HOPE Trial and the SMART Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gynecologic Cancer"
      ],
      "interventions": [
        {
          "name": "Fitbit Zip",
          "type": "DEVICE"
        },
        {
          "name": "HOPE App",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        },
        {
          "name": "Fitbit Charge 2",
          "type": "DEVICE"
        },
        {
          "name": "SMART Study Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 102,
      "start_date": "2017-04-12",
      "completion_date": "2020-09-02",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03022032"
    },
    {
      "nct_id": "NCT04834726",
      "title": "COVID-19 Vaccine Text Outreach",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Opt-In (Call-Back)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Opt-in (In-Bound)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Endorsement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Scarcity",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Opt-Out Framing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Phone Call",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 19554,
      "start_date": "2021-04-29",
      "completion_date": "2021-07-06",
      "has_results": true,
      "last_update_posted_date": "2023-03-27",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04834726"
    },
    {
      "nct_id": "NCT00700778",
      "title": "Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "BRCA1 Mutation",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant human chorionic gonadotropin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "needle biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 40 Years · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2008-07",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00700778"
    },
    {
      "nct_id": "NCT02954978",
      "title": "Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Parkinsons Disease With Dementia"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib 150mg oral capsule [Tasigna]",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib 300mg oral capsule [Tasigna]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 75,
      "start_date": "2017-01",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-30T13:26:41.806Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02954978"
    }
  ]
}